17-beta-hydroxysteroid dehydrogenase type 3 (17-beta-HSD 3) (Estradiol 17-beta-dehydrogenase 2) (EC 1.1.1.62) (Short chain dehydrogenase/reductase family 12C member 2) (Testicular 17-beta-hydroxysteroid dehydrogenase) (Testosterone 17-beta-dehydrogenase 3) (EC 1.1.1.64)
1_MGDVL 6_ EQFFI 11_ LTGLL 16_ VCLAC 21_ LAKCV 26_ RFSRC 31_ VLLNY 36_ WKVLP 41_ KSFLR 46_ SMGQW 51_ AVITG 56_ AGDGI 61_ GKAYS 66_ FELAK 71_ RGLNV 76_ VLISR 81_ TLEKL 86_ EAIAT 91_ EIERT 96_ TGRSV 101_ KIIQA 106_ DFTKD 111_ DIYEH 116_ IKEKL 121_ AGLEI 126_ GILVN 131_ NVGML 136_ PNLLP 141_ SHFLN 146_ APDEI 151_ QSLIH 156_ CNITS 161_ VVKMT 166_ QLILK 171_ HMESR 176_ QKGLI 181_ LNISS 186_ GIALF 191_ PWPLY 196_ SMYSA 201_ SKAFV 206_ CAFSK 211_ ALQEE 216_ YKAKE 221_ VIIQV 226_ LTPYA 231_ VSTAM 236_ TKYLN 241_ TNVIT 246_ KTADE 251_ FVKES 256_ LNYVT 261_ IGGET 266_ CGCLA 271_ HEILA 276_ GFLSL 281_ IPAWA 286_ FYSGA 291_ FQRLL 296_ LTHYV 301_AYLKL
1: Catalyzes the conversion of 17-oxosteroids to 17beta-hydroxysteroids (PubMed:16216911, PubMed:26545797, PubMed:27927697, PubMed:8075637). Favors the reduction of androstenedione to testosterone (PubMed:16216911, PubMed:26545797, PubMed:27927697). Testosterone is the key androgen driving male development and function (PubMed:8075637). Uses NADPH while the two other EDH17B enzymes use NADH (PubMed:16216911, PubMed:26545797, PubMed:8075637). Androgens such as epiandrosterone, dehydroepiandrosterone, androsterone and androstanedione are accepted as substrates and reduced at C-17 (PubMed:16216911). Can reduce 11-ketoandrostenedione as well as 11beta-hydroxyandrostenedione at C-17 to the respective testosterone forms (PubMed:16216911, PubMed:27927697)